听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览Lancet HIV期刊下所有文献
  • Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.

    abstract:BACKGROUND:Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality. We aimed to estimate the effect of isoniazid preventive therapy given wit...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,meta分析

    doi:10.1016/S2352-3018(20)30299-X

    authors: Ross JM,Badje A,Rangaka MX,Walker AS,Shapiro AE,Thomas KK,Anglaret X,Eholie S,Gabillard D,Boulle A,Maartens G,Wilkinson RJ,Ford N,Golub JE,Williams BG,Barnabas RV

    更新日期:2021-01-01 00:00:00

  • Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.

    abstract:BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30279-4

    authors: Sharma M,Mudimu E,Simeon K,Bershteyn A,Dorward J,Violette LR,Akullian A,Abdool Karim SS,Celum C,Garrett N,Drain PK

    更新日期:2020-12-18 00:00:00

  • PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.

    abstract:BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in orde...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30119-3

    authors: Poteat T,Malik M,van der Merwe LLA,Cloete A,Adams D,Nonyane BAS,Wirtz AL

    更新日期:2020-12-01 00:00:00

  • Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n

    abstract:BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(20)30241-1

    authors: Venter WDF,Sokhela S,Simmons B,Moorhouse M,Fairlie L,Mashabane N,Serenata C,Akpomiemie G,Masenya M,Qavi A,Chandiwana N,McCann K,Norris S,Chersich M,Maartens G,Lalla-Edward S,Vos A,Clayden P,Abrams E,Arulappan N,Hi

    更新日期:2020-10-01 00:00:00

  • Modern diagnostic technologies for HIV.

    abstract::Novel diagnostic technologies, including nanotechnology, microfluidics, -omics science, next-generation sequencing, genomics big data, and machine learning, could contribute to meeting the UNAIDS 95-95-95 targets to end the HIV epidemic by 2030. Novel technologies include multiplexed technologies (including biomarker-...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(20)30190-9

    authors: Pai NP,Karellis A,Kim J,Peter T

    更新日期:2020-08-01 00:00:00

  • Ending the HIV epidemic in the USA: an economic modelling study in six cities.

    abstract:BACKGROUND:The HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA. METHODS:...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30033-3

    authors: Nosyk B,Zang X,Krebs E,Enns B,Min JE,Behrends CN,Del Rio C,Dombrowski JC,Feaster DJ,Golden M,Marshall BDL,Mehta SH,Metsch LR,Pandya A,Schackman BR,Shoptaw S,Strathdee SA,Localized HIV Modeling Study Group.

    更新日期:2020-07-01 00:00:00

  • Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.

    abstract:BACKGROUND:Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy. We compared safety and e...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(20)30038-2

    authors: João EC,Morrison RL,Shapiro DE,Chakhtoura N,Gouvèa MIS,de Lourdes B Teixeira M,Fuller TL,Mmbaga BT,Ngocho JS,Njau BN,Violari A,Mathiba R,Essack Z,Pilotto JHS,Moreira LF,Rolon MJ,Cahn P,Prommas S,Cressey TR,Chokephai

    更新日期:2020-05-01 00:00:00

  • Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.

    abstract:BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverag...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(19)30373-X

    authors: Tan J,Altice FL,Madden LM,Zelenev A

    更新日期:2020-02-01 00:00:00

  • Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.

    abstract:BACKGROUND:Tuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care ...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(19)30266-8

    authors: Grant AD,Charalambous S,Tlali M,Karat AS,Dorman SE,Hoffmann CJ,Johnson S,Vassall A,Churchyard GJ,Fielding KL

    更新日期:2020-01-01 00:00:00

  • Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.

    abstract::Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30193-6

    authors: Penazzato M,Townsend CL,Rakhmanina N,Cheng Y,Archary M,Cressey TR,Kim MH,Musiime V,Turkova A,Ruel TD,Rabie H,Sugandhi N,Rojo P,Doherty M,Abrams EJ,PADO4 participants.

    更新日期:2019-09-01 00:00:00

  • Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

    abstract:BACKGROUND:An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in se...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(19)30145-6

    authors: Keller MJ,Wood L,Billingsley JM,Ray LL,Goymer J,Sinclair S,McGinn AP,Marzinke MA,Frank B,Srinivasan S,Liu C,Atrio JM,Espinoza L,Mugo N,Spiegel HML,Anderson PL,Fredricks DN,Hendrix CW,Marrazzo J,Bosinger SE,Herold

    更新日期:2019-08-01 00:00:00

  • Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.

    abstract:BACKGROUND:Pilot studies suggest that ritonavir-boosted darunavir could show high efficacy at doses below those currently approved. We investigated whether switch to 400 mg of darunavir boosted with 100 mg ritonavir once daily could show equivalent efficacy to continuation of ritonavir-boosted lopinavir (a protease inh...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(19)30081-5

    authors: Venter WDF,Moorhouse M,Sokhela S,Serenata C,Akpomiemie G,Qavi A,Mashabane N,Arulappan N,Sim JW,Sinxadi PZ,Wiesner L,Maharaj E,Wallis C,Boyles T,Ripin D,Stacey S,Chitauri G,Hill A

    更新日期:2019-07-01 00:00:00

  • Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

    abstract:BACKGROUND:Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of HIV-1-infection and might be better tolerated than other integrase inhibitor-based single-tablet regimens, but long-term outcomes data are not available. We assessed the efficacy...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(19)30077-3

    authors: Wohl DA,Yazdanpanah Y,Baumgarten A,Clarke A,Thompson MA,Brinson C,Hagins D,Ramgopal MN,Antinori A,Wei X,Acosta R,Collins SE,Brainard D,Martin H

    更新日期:2019-06-01 00:00:00

  • Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

    abstract::The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30082-7

    authors: Moore CL,Stöhr W,Crook AM,Richert L,Leliévre JD,Pantaleo G,García F,Vella S,Lévy Y,Thiébaut R,McCormack S

    更新日期:2019-05-01 00:00:00

  • Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz.

    abstract::South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30249-2

    authors: Black V,Schwartz SR

    更新日期:2018-12-01 00:00:00

  • Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings.

    abstract::In our work as clinicians, researchers, and immigrant rights advocates, we have noted increased anxiety about the possibility of deportation and disruptions in care among immigrants with HIV. Before the 2016 US elections, patients rarely asked about HIV treatment in their home countries. However, since the increase in...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30074-2

    authors: Page KR,Grieb SD,Nieves-Lugo K,Yamanis T,Taylor H,Martinez O,Yamasaki Y,Limaye R,Davis W,Beyrer C,Zea MC

    更新日期:2018-10-01 00:00:00

  • Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey.

    abstract:BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30104-8

    authors: Kharsany ABM,Cawood C,Khanyile D,Lewis L,Grobler A,Puren A,Govender K,George G,Beckett S,Samsunder N,Madurai S,Toledo C,Chipeta Z,Glenshaw M,Hersey S,Abdool Karim Q

    更新日期:2018-08-01 00:00:00

  • Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph

    abstract:BACKGROUND:Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(18)30091-2

    authors: Daar ES,DeJesus E,Ruane P,Crofoot G,Oguchi G,Creticos C,Rockstroh JK,Molina JM,Koenig E,Liu YP,Custodio J,Andreatta K,Graham H,Cheng A,Martin H,Quirk E

    更新日期:2018-07-01 00:00:00

  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

    abstract:BACKGROUND:Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase im...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(18)30071-7

    authors: Bekker LG,Moodie Z,Grunenberg N,Laher F,Tomaras GD,Cohen KW,Allen M,Malahleha M,Mngadi K,Daniels B,Innes C,Bentley C,Frahm N,Morris DE,Morris L,Mkhize NN,Montefiori DC,Sarzotti-Kelsoe M,Grant S,Yu C,Mehra VL,Pen

    更新日期:2018-07-01 00:00:00

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

    abstract:BACKGROUND:Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(18)30021-3

    authors: Molina JM,Squires K,Sax PE,Cahn P,Lombaard J,DeJesus E,Lai MT,Xu X,Rodgers A,Lupinacci L,Kumar S,Sklar P,Nguyen BY,Hanna GJ,Hwang C,DRIVE-FORWARD Study Group.

    更新日期:2018-05-01 00:00:00

  • Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action.

    abstract::Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30005-5

    authors: Penazzato M,Watkins M,Morin S,Lewis L,Pascual F,Vicari M,Lee J,Hargreaves S,Doherty M,Siberry GK

    更新日期:2018-05-01 00:00:00

  • Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.

    abstract:BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30205-9

    authors: Iwuji CC,Orne-Gliemann J,Larmarange J,Balestre E,Thiebaut R,Tanser F,Okesola N,Makowa T,Dreyer J,Herbst K,McGrath N,Bärnighausen T,Boyer S,De Oliveira T,Rekacewicz C,Bazin B,Newell ML,Pillay D,Dabis F,ANRS 12249 Tas

    更新日期:2018-03-01 00:00:00

  • Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study.

    abstract:BACKGROUND:Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services. METHODS:To create a retrospective cohort of all adults with HI...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30209-6

    authors: Loeliger KB,Altice FL,Desai MM,Ciarleglio MM,Gallagher C,Meyer JP

    更新日期:2018-02-01 00:00:00

  • Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial.

    abstract:BACKGROUND:HIV testing is the important entry point for HIV care and prevention service, but uptake of HIV testing and thus coverage of antiretroviral therapy are much lower in older children and adolescents than in adults. We investigated the effect of economic incentives provided to caregivers of children aged 8-17 y...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30176-5

    authors: Kranzer K,Simms V,Bandason T,Dauya E,McHugh G,Munyati S,Chonzi P,Dakshina S,Mujuru H,Weiss HA,Ferrand RA

    更新日期:2018-02-01 00:00:00

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr

    abstract:BACKGROUND:Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhi...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(17)30179-0

    authors: Orkin C,Molina JM,Negredo E,Arribas JR,Gathe J,Eron JJ,Van Landuyt E,Lathouwers E,Hufkens V,Petrovic R,Vanveggel S,Opsomer M,EMERALD study group.

    更新日期:2018-01-01 00:00:00

  • Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

    abstract:BACKGROUND:Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetic...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(17)30068-1

    authors: Markowitz M,Frank I,Grant RM,Mayer KH,Elion R,Goldstein D,Fisher C,Sobieszczyk ME,Gallant JE,Van Tieu H,Weinberg W,Margolis DA,Hudson KJ,Stancil BS,Ford SL,Patel P,Gould E,Rinehart AR,Smith KY,Spreen WR

    更新日期:2017-08-01 00:00:00

  • From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.

    abstract:BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30224-7

    authors: Haber N,Tanser F,Bor J,Naidu K,Mutevedzi T,Herbst K,Porter K,Pillay D,Bärnighausen T

    更新日期:2017-05-01 00:00:00

  • PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.

    abstract:BACKGROUND:The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP)...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30021-8

    authors: Cremin I,McKinnon L,Kimani J,Cherutich P,Gakii G,Muriuki F,Kripke K,Hecht R,Kiragu M,Smith J,Hinsley W,Gelmon L,Hallett TB

    更新日期:2017-05-01 00:00:00

  • Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

    abstract:BACKGROUND:All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we d...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30016-4

    authors: Sax PE,DeJesus E,Crofoot G,Ward D,Benson P,Dretler R,Mills A,Brinson C,Peloquin J,Wei X,White K,Cheng A,Martin H,Quirk E

    更新日期:2017-04-01 00:00:00

  • Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.

    abstract:BACKGROUND:The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. METHODS:We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Elig...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30015-2

    authors: Grinsztejn B,Jalil EM,Monteiro L,Velasque L,Moreira RI,Garcia AC,Castro CV,Krüger A,Luz PM,Liu AY,McFarland W,Buchbinder S,Veloso VG,Wilson EC,Transcender Study Team.

    更新日期:2017-04-01 00:00:00

  • Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.

    abstract:BACKGROUND:Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with that of ART star...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/S2352-3018(16)30195-3

    authors: Uthman OA,Nachega JB,Anderson J,Kanters S,Mills EJ,Renaud F,Essajee S,Doherty MC,Mofenson LM

    更新日期:2017-01-01 00:00:00

  • Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

    abstract:BACKGROUND:As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rolled out internationally, strategies to maintain effectiveness and to minimise adverse effects merit consideration. In this study, we aimed to assess reductions in renal function a...

    journal_title:The lancet. HIV

    pub_type: 临床试验,杂志文章

    doi:10.1016/S2352-3018(16)30153-9

    authors: Gandhi M,Glidden DV,Mayer K,Schechter M,Buchbinder S,Grinsztejn B,Hosek S,Casapia M,Guanira J,Bekker LG,Louie A,Horng H,Benet LZ,Liu A,Grant RM

    更新日期:2016-11-01 00:00:00

  • Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.

    abstract:BACKGROUND:Home HIV testing and counselling (HTC) achieves high levels of HIV testing and linkage to care. Periodic home HTC, particularly targeted to those with high HIV viral load, might facilitate expansion of antiretroviral therapy (ART) coverage. We used a mathematical model to assess the effect of periodic home H...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30009-1

    authors: Ying R,Sharma M,Celum C,Baeten JM,van Rooyen H,Hughes JP,Garnett G,Barnabas RV

    更新日期:2016-06-01 00:00:00

  • Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.

    abstract:BACKGROUND:HIV evolves rapidly and therefore infections with similar genetic sequences are likely linked by recent transmission events. Clusters of related infections can represent subpopulations with high rates of transmission. We describe the implementation of an automated near real-time system to monitor and charact...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)00046-1

    authors: Poon AF,Gustafson R,Daly P,Zerr L,Demlow SE,Wong J,Woods CK,Hogg RS,Krajden M,Moore D,Kendall P,Montaner JS,Harrigan PR

    更新日期:2016-05-01 00:00:00

  • Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial.

    abstract:BACKGROUND:Novel strategies are needed to increase retention in and uptake of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa. We aimed to determine whether small, increasing cash payments, which were conditional on attendance at scheduled clinic visits and receipt of proposed serv...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(15)00247-7

    authors: Yotebieng M,Thirumurthy H,Moracco KE,Kawende B,Chalachala JL,Wenzi LK,Ravelomanana NL,Edmonds A,Thompson D,Okitolonda EW,Behets F

    更新日期:2016-02-01 00:00:00

  • Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

    abstract:BACKGROUND:Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovir...

    journal_title:The lancet. HIV

    pub_type: 临床试验,杂志文章

    doi:10.1016/S2352-3018(15)00211-8

    authors: Mocroft A,Lundgren JD,Ross M,Fux CA,Reiss P,Moranne O,Morlat P,Monforte Ad,Kirk O,Ryom L,Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

    更新日期:2016-01-01 00:00:00

  • Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.

    abstract:BACKGROUND:BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present th...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(15)00177-0

    authors: Lalezari JP,Latiff GH,Brinson C,Echevarría J,Treviño-Pérez S,Bogner JR,Thompson M,Fourie J,Sussmann Pena OA,Mendo Urbina FC,Martins M,Diaconescu IG,Stock DA,Joshi SR,Hanna GJ,Lataillade M,AI438011 study team.

    更新日期:2015-10-01 00:00:00

  • Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

    abstract:BACKGROUND:As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of ...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究

    doi:10.1016/S2352-3018(15)00113-7

    authors: Cornell M,Johnson LF,Schomaker M,Tanser F,Maskew M,Wood R,Prozesky H,Giddy J,Stinson K,Egger M,Boulle A,Myer L,International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

    更新日期:2015-09-01 00:00:00

  • CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

    abstract:BACKGROUND:In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. METHODS:We did an analysis of the...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(15)00006-5

    authors: Mussini C,Lorenzini P,Cozzi-Lepri A,Lapadula G,Marchetti G,Nicastri E,Cingolani A,Lichtner M,Antinori A,Gori A,d'Arminio Monforte A,Icona Foundation Study Group.

    更新日期:2015-03-01 00:00:00

  • Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

    abstract:BACKGROUND:WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART w...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(14)00061-7

    authors: Boyd MA,Moore CL,Molina JM,Wood R,Madero JS,Wolff M,Ruxrungtham K,Losso M,Renjifo B,Teppler H,Kelleher AD,Amin J,Emery S,Cooper DA,SECOND-LINE study group.

    更新日期:2015-02-01 00:00:00

43 条记录 1/2 页 « 12 »